Harry Fisch Purchases 10,000 Shares of Female Health (NASDAQ:VERU) Stock

Female Health (NASDAQ:VERU) Director Harry Fisch bought 10,000 shares of the business’s stock in a transaction on Monday, March 12th. The stock was purchased at an average cost of $1.80 per share, with a total value of $18,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Harry Fisch also recently made the following trade(s):

  • On Friday, March 16th, Harry Fisch bought 5,000 shares of Female Health stock. The stock was purchased at an average cost of $1.96 per share, with a total value of $9,800.00.
  • On Wednesday, March 14th, Harry Fisch bought 10,000 shares of Female Health stock. The stock was purchased at an average cost of $1.87 per share, with a total value of $18,700.00.
  • On Friday, March 9th, Harry Fisch bought 10,000 shares of Female Health stock. The stock was purchased at an average cost of $1.88 per share, with a total value of $18,800.00.
  • On Wednesday, March 7th, Harry Fisch bought 24,000 shares of Female Health stock. The stock was purchased at an average cost of $1.62 per share, with a total value of $38,880.00.

NASDAQ:VERU opened at $1.82 on Friday. The company has a market cap of $96.32, a PE ratio of -7.28 and a beta of 0.69. Female Health has a fifty-two week low of $0.90 and a fifty-two week high of $3.00.

Female Health (NASDAQ:VERU) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $2.59 million during the quarter, compared to analyst estimates of $5.30 million. Female Health had a negative return on equity of 17.63% and a negative net margin of 73.11%. sell-side analysts forecast that Female Health will post -0.14 EPS for the current year.

Several analysts have issued reports on VERU shares. HC Wainwright set a $5.00 target price on Female Health and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine raised Female Health from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research lowered Female Health from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th.

WARNING: This piece of content was originally published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/07/veru-inc-veru-director-buys-18000-00-in-stock/2038365.html.

About Female Health

Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Insider Buying and Selling by Quarter for Female Health (NASDAQ:VERU)

Receive News & Ratings for Female Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.